| Schedule of non-controlling interests in consolidated entities |
Non-controlling interests in consolidated entities are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the twelve months ended
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2019
|
|
December 31, 2019
|
|
As of December 31, 2019
|
|
|
|
|
|
|
|
|
|
Net loss attributable to non-
|
|
Non-controlling interests
|
|
Non-controlling
|
|
|
($ in thousands)
|
|
NCI equity share
|
|
controlling interests
|
|
in consolidated entities
|
|
ownership
|
|
|
Aevitas
|
|
$
|
(1,249)
|
|
$
|
(694)
|
|
$
|
(1,943)
|
|
35.8
|
%
|
|
Avenue 2
|
|
|
24,269
|
|
|
(19,011)
|
|
|
5,258
|
|
77.3
|
%
|
|
Baergic
|
|
|
23
|
|
|
(1,162)
|
|
|
(1,139)
|
|
33.0
|
%
|
|
Cellvation
|
|
|
(732)
|
|
|
(158)
|
|
|
(890)
|
|
20.6
|
%
|
|
Checkpoint 1
|
|
|
29,389
|
|
|
(14,687)
|
|
|
14,702
|
|
78.0
|
%
|
|
Coronado SO
|
|
|
(290)
|
|
|
—
|
|
|
(290)
|
|
13.0
|
%
|
|
Cyprium
|
|
|
(320)
|
|
|
(99)
|
|
|
(419)
|
|
10.6
|
%
|
|
Helocyte
|
|
|
(4,322)
|
|
|
(402)
|
|
|
(4,724)
|
|
19.3
|
%
|
|
JMC
|
|
|
(211)
|
|
|
325
|
|
|
114
|
|
6.9
|
%
|
|
Mustang 2
|
|
|
62,025
|
|
|
(25,727)
|
|
|
36,298
|
|
70.3
|
%
|
|
Tamid
|
|
|
(565)
|
|
|
(85)
|
|
|
(650)
|
|
22.8
|
%
|
|
Total
|
|
$
|
108,017
|
|
$
|
(61,700)
|
|
$
|
46,317
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the twelve months ended
|
|
|
|
|
|
|
|
|
As of December 31, 2018
|
|
December 31, 2018
|
|
As of December 31, 2018
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to
|
|
Non-controlling interests in
|
|
Non-controlling
|
|
|
($ in thousands)
|
|
NCI equity share
|
|
non-controlling interests
|
|
consolidated entities
|
|
ownership
|
|
|
Aevitas
|
|
$
|
(474)
|
|
$
|
(606)
|
|
$
|
(1,080)
|
|
36.1
|
%
|
|
Avenue 2
|
|
|
13,326
|
|
|
(13,735)
|
|
|
(409)
|
|
64.81
|
%
|
|
Caelum3
|
|
|
(2,436)
|
|
|
(2,413)
|
|
|
(4,849)
|
|
36.8
|
%
|
|
Cellvation
|
|
|
(457)
|
|
|
(185)
|
|
|
(642)
|
|
21.1
|
%
|
|
Checkpoint 1
|
|
|
31,648
|
|
|
(23,470)
|
|
|
8,178
|
|
69.3
|
%
|
|
Coronado SO
|
|
|
(290)
|
|
|
—
|
|
|
(290)
|
|
13.0
|
%
|
|
Cyprium
|
|
|
(210)
|
|
|
(62)
|
|
|
(272)
|
|
10.8
|
%
|
|
Helocyte
|
|
|
(3,372)
|
|
|
(684)
|
|
|
(4,056)
|
|
19.8
|
%
|
|
JMC
|
|
|
(475)
|
|
|
245
|
|
|
(230)
|
|
6.9
|
%
|
|
Mustang 2
|
|
|
38,631
|
|
|
(16,628)
|
|
|
22,003
|
|
60.5
|
%
|
|
Tamid
|
|
|
(211)
|
|
|
(251)
|
|
|
(462)
|
|
23.4
|
%
|
|
Total
|
|
$
|
75,680
|
|
$
|
(57,789)
|
|
$
|
17,891
|
|
|
|
Note 1: Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.
Note 2: Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.
Note 3: Effective January 30, 2019, Caelum ceased to be a controlled Fortress entity and as such is no longer consolidated.
|